Defining Treatment‐Resistant Bipolar Depression: Recommendations From the ISBD Task Force
Bipolar Disorders · 2025-09 · 27 (6) · 411-423
DOI: 10.1111/bdi.70048 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bipolar Disorders, online erschienen am 13.08.2025. Verfasst von Eduard Vieta und 29 weiteren Autor:innen. Beteiligte Einrichtung: Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Antidepressive Agents, Bipolar Disorder, Depressive Disorder, Treatment-Resistant. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS.
Themen: Depression
Abstract (Originalsprache)
Objective
Despite the availability of approved treatments, a substantial proportion of patients with bipolar disorder experience treatment‐resistant bipolar depression (TRBD), characterized by persistent depressive symptoms unresponsive to standard therapies. However, a universally accepted definition of TRBD is lacking. This consensus document, developed by the International Society for Bipolar Disorders (ISBD) Task Force on TRBD, aims to provide a standardized definition of TRBD to facilitate clinical trials, research, and treatment strategies.
Methods
The Task Force employed a literature review, clinical trials analysis, and expert consensus meetings to define TRBD.
Results
TRBD was defined as the failure to achieve a significant and sustained clinical response after at least two approved and adequately dosed pharmacological treatments, administered for a sufficient duration with treatment adherence. For bipolar I (BD‐I) depression, approved treatments included quetiapine (300–600 mg/day for ≥ 8 weeks), lurasidone (20–120 mg/day for ≥ 6 weeks), the combination of olanzapine (6–12 mg/day) and fluoxetine (25–75 mg/day for ≥ 8 weeks), cariprazine (1.5–3 mg/day for ≥ 6 weeks), and lumateperone (42 mg/day for ≥ 6 weeks). For bipolar II (BD‐II) depression, approved treatments included quetiapine (300–600 mg/day for ≥ 8 weeks) and lumateperone (42 mg/day for ≥ 6 weeks).
Conclusion
This consensus definition aims to provide clarity for clinical trials, improve consistency in research, and guide treatment approaches and inform regulatory pathways. It represents a foundational step in addressing the unmet needs in TRBD and promoting the development of innovative therapeutic strategies. Future efforts will focus on adapting the definition to better align with real‐world clinical challenges and optimize patient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona, Barcelona, Spain.
- Departament de Medicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Institut de Neurociències (UBNeuro), Barcelona, Spain.
- Institut D'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
ORCID-Profile: Eduard Vieta, Roger S McIntyre, Trisha Suppes, Balwinder Singh, Michael Berk, Holly A Swartz, Gerard Anmella Diaz, Diego Hidalgo-Mazzei, Mauricio Tohen, Isabella Pacchiarotti, Paula Villela Nunes, Robert Post, Giovanna Fico
Förderung
- NCATS NIH HHS
Zitieren
APA
Vieta, E., McIntyre, R. S., Suppes, T., Van Rheenen, T. E., Singh, B., Miskowiak, K. W., Young, A. H., Yatham, L. N., Ha, K., Berk, M., Swartz, H. A., Henry, C., Stefanovic, M. P., Diaz, G. A., Ozerdem, A., Cubała, W. J., Hidalgo-Mazzei, D., Tohen, M., Pacchiarotti, I., …, & Fico, G. (2025). Defining Treatment‐Resistant Bipolar Depression: Recommendations From the ISBD Task Force. Bipolar Disorders, 27(6), 411-423. https://doi.org/10.1111/bdi.70048
Vancouver
Vieta E, McIntyre RS, Suppes T, Van Rheenen TE, Singh B, Miskowiak KW, et al. Defining Treatment‐Resistant Bipolar Depression: Recommendations From the ISBD Task Force. Bipolar Disorders. 2025;27(6):411-423. doi:10.1111/bdi.70048
BibTeX
@article{Vieta2025,
author = {Vieta, Eduard and McIntyre, Roger S and Suppes, Trisha and Van Rheenen, Tamsyn E and Singh, Balwinder and Miskowiak, Kamilla Woznica and Young, Allan H and Yatham, Lakshmi N and Ha, Kyooseob and Berk, Michael and Swartz, Holly A and Henry, Chantal and Stefanovic, Maja Pantovic and Diaz, Gerard Anmella and Ozerdem, Aysegul and Cubała, Wiesław J and Hidalgo-Mazzei, Diego and Tohen, Mauricio and Pacchiarotti, Isabella and Nunes, Paula Villela and Lopez-Jaramillo, Carlos and Gonzalez-Pinto, Ana and Brambilla, Paolo and Post, Robert and Soares, Jair C and Bauer, Michael and Andreazza, Ana C and Fradera, Xavier Justes and Cosials-Lopez, Montserrat and Fico, Giovanna},
title = {Defining Treatment‐Resistant Bipolar Depression: Recommendations From the ISBD Task Force},
journal = {Bipolar Disorders},
year = {2025},
volume = {27},
number = {6},
pages = {411--423},
doi = {10.1111/bdi.70048}
}
EUVIMED